Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
| Revenue (Most Recent Fiscal Year) | $4.07B |
| Net Income (Most Recent Fiscal Year) | $560.12M |
| PE Ratio (Current Year Earnings Estimate) | 52.50 |
| PE Ratio (Trailing 12 Months) | 6.43 |
| PEG Ratio (Long Term Growth Estimate) | 4.67 |
| Price to Sales Ratio (Trailing 12 Months) | 1.64 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.60 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.57 |
| Pre-Tax Margin (Trailing 12 Months) | 8.91% |
| Net Margin (Trailing 12 Months) | 11.86% |
| Return on Equity (Trailing 12 Months) | 26.62% |
| Return on Assets (Trailing 12 Months) | 9.14% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.38 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.28 |
| Inventory Turnover (Trailing 12 Months) | 0.89 |
| Book Value per Share (Most Recent Fiscal Quarter) | $67.72 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.60 |
| Earnings per Share (Most Recent Fiscal Year) | $17.95 |
| Diluted Earnings per Share (Trailing 12 Months) | $7.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 61.65M |
| Free Float | 59.06M |
| Market Capitalization | $6.67B |
| Average Volume (Last 20 Days) | 1.30M |
| Beta (Past 60 Months) | 0.38 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 89.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |